Loading...
•
Dec 26, 2020
Haemonetics Q3 2021 Earnings Report
Haemonetics' Q3 2021 financial results were reported, showing revenue decrease but improved profitability driven by Operational Excellence Program and cost management.
Key Takeaways
Haemonetics reported a 7.2% decrease in revenue to $240.4 million for Q3 2021, impacted by COVID-19. However, profitability improved due to the Operational Excellence Program and cost management. The company is progressing with NexSys® and TEG® adoption and investing in innovation.
Q3 revenue decreased by 7% to $240 million.
Earnings per diluted share was $0.62, while adjusted earnings per diluted share was $0.81.
Gross margin was 50.0%, up 60 basis points compared to the prior year.
Operating income was $40.4 million, with an operating margin of 16.8%.
Haemonetics
Haemonetics
Haemonetics Revenue by Segment
Revenue by Segment
Plasma Revenue
CapyFin.comBlood Center Revenue
CapyFin.comHospital Revenue
CapyFin.comRevenue & Expenses
Visualization of income flow from segment revenue to net income